Fenson
Introduction "fenson" refers to genetic variations associated with pulmonary function, specifically Forced Expiratory Flow between 25% and 75% of vital capacity (FEF25-75), a key measure of airflow obstruction in the small airways of the lungs. This trait, including its slope over time (fefslope) and percent predicted values (ppfef25-75), has been a subject of genome-wide association studies (GWAS) to identify contributing genetic factors. [1] Understanding the genetic underpinnings of pulmonary function is crucial for identifying individuals at risk for respiratory diseases and for developing targeted interventions.
Biological Basis
Pulmonary function, encompassing measures like FEF25-75, reflects the efficiency of the respiratory system in moving air in and out of the lungs. Genetic factors play a significant role in determining an individual's lung capacity and airflow dynamics. [1] Genetic variations, such as single nucleotide polymorphisms (SNPs), can influence the development and maintenance of lung structure and function. Studies have identified several candidate gene regions associated with pulmonary function measures. For example, SNPs with low p-values have been localized to regions containing genes such as COL1A2, ADARB1, SNTG1, RHBDD1, NID2, IL6R, and SYT10. Other identified intronic SNPs were found in genes like CCBL2, LRRC9, PAX3, LIPF, MTHFD1L, and KIAA1797. [1] These genes are implicated in various cellular processes that could affect lung health, from structural integrity to inflammatory responses and metabolic pathways.
Clinical Relevance
The clinical relevance of fenson, or FEF25-75, is substantial as it serves as an indicator of small airway function, which can be affected early in the course of chronic obstructive pulmonary disease (COPD), asthma, and other respiratory conditions. Declines in FEF25-75 can precede more noticeable changes in other spirometric measures like Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC). [1] Identifying genetic predispositions to impaired pulmonary function can aid in early risk assessment, allowing for preventative strategies or earlier therapeutic interventions. This is particularly important given the high heritability of some pulmonary function phenotypes. [1]
Social Importance
From a societal perspective, understanding the genetic components of pulmonary function like fenson has broad implications for public health. Respiratory diseases are a major cause of morbidity and mortality worldwide. By elucidating the genetic architecture of these traits, researchers can contribute to personalized medicine approaches, where genetic profiles inform disease risk prediction, prognosis, and treatment selection. This knowledge can also guide the development of novel pharmacological targets and public health campaigns aimed at mitigating environmental risks in genetically susceptible populations, ultimately improving the quality of life and reducing the healthcare burden associated with lung disorders.
Methodological and Statistical Considerations
Genome-wide association studies (GWAS) often encounter challenges in detecting all relevant genetic effects due to limitations in sample size and the stringent statistical corrections required for multiple testing. While studies may possess high power to identify variants with substantial phenotypic impact, those with smaller effect sizes often necessitate larger cohorts or meta-analyses for discovery . Elevated LDL-cholesterol is a well-established risk factor for atherosclerosis and cardiovascular disease, making these HMGCR variants relevant to the broader cardiovascular aspects of fenson. Additionally, variations in genes like BCMO1 (beta-carotene 15,15'-monooxygenase 1), which is responsible for converting beta-carotene into vitamin A, have been found to affect circulating levels of carotenoids. [2] Carotenoid levels are important for antioxidant defense and overall metabolic health, further contributing to an individual's profile related to fenson.
Other notable genetic variants are implicated in metabolic regulation and inflammatory processes. A variant of the transcription factor 7-like 2 (TCF7L2) gene, for instance, is known to confer an increased risk of type 2 diabetes by affecting insulin secretion and glucose homeostasis. [3] Similarly, polymorphisms in the HNF1A (hepatocyte nuclear factor-1 alpha) gene, which encodes a transcription factor critical for pancreatic beta-cell function and liver metabolism, are associated with C-reactive protein levels. [4] C-reactive protein is a marker of systemic inflammation, and both type 2 diabetes and chronic inflammation are significant contributors to cardiovascular disease and overall metabolic dysfunction, central to understanding fenson.
Several SNPs have been linked to specific cardiac structural and functional parameters, which are key components of fenson. For example, rs10510001, rs10510000, rs10509999, and rs10495300 are associated with various echocardiographic dimensions, including left ventricular (LV) diastolic and systolic dimensions, LV wall thickness, LV fractional shortening, left atrial diameter, and aortic root diameter. [5] These variations can influence the heart's size, pumping efficiency, and overall structure, thereby affecting cardiac health and contributing to the manifestation of cardiovascular aspects within the fenson phenotype. Such changes in cardiac dimensions can be indicators of subclinical heart disease or precursors to more severe conditions.
Beyond specific genes, broader chromosomal regions can also harbor variants impacting fenson. A common variant on chromosome 9p21 has been consistently linked to an increased risk of myocardial infarction and coronary heart disease. [6] While specific genes within this region are still under investigation, the strong association highlights its importance in cardiovascular susceptibility. These genetic predispositions collectively contribute to an individual's overall risk profile for conditions such as atherosclerosis, metabolic syndrome, and cardiac dysfunction, which are integral to the comprehensive understanding of fenson.
Essential Fatty Acid Conversion and Desaturase Activity
The human body relies on a complex network of enzymes to synthesize and modify fatty acids, crucial components for various biological structures and functions. A key player in this process is the FADS1 gene, which encodes the delta-5 desaturase enzyme. [7] This enzyme is indispensable for converting essential dietary fatty acids, specifically linoleic acid (C18:2) from the omega-6 pathway and alpha-linolenic acid (C18:3) from the omega-3 pathway, into longer-chain poly-unsaturated fatty acids (LCPUFAs). [7] While un- and monosaturated fatty acids up to 18 carbons, such as palmitic acid (C16:0), stearic acid (C18:0), and oleic acid (C18:1), can be synthesized de novo within the body, the production of LCPUFAs like arachidonyl-CoA (C20:4) from eicosatrienoyl-CoA (C20:3) is directly dependent on the catalytic activity of delta-5 desaturase. [7]
Glycerophospholipid Biosynthesis and Cellular Roles
Beyond their synthesis, fatty acids are integrated into more complex lipid structures, such as glycerophospholipids, through pathways like the Kennedy pathway. In this pathway, glycerol-phosphatidylcholines (PC) with diverse fatty acid side chains are generated by linking two fatty acid moieties to a glycerol 3-phosphate molecule. [7] This initial step is followed by a dephosphorylation and the subsequent addition of a phosphocholine moiety to form the complete phosphatidylcholine molecule. [7] These glycerophospholipids, including PC, phosphatidylethanolamines (PE), and phosphatidylinositols (PI), are fundamental components of cellular membranes, contributing to their structural integrity and fluidity, and also play vital roles as signaling molecules in various cellular processes. [7] Many of these complex lipids, particularly those with four double bonds, are formed from an arachidonyl-moiety (C20:4) combined with a palmitoyl- (C16:0) or stearoyl-moiety (C18:0). [7]
Genetic Influence on Lipid Metabolic Efficiency
Genetic variations, particularly polymorphisms within the FADS1 gene, can significantly impact the efficiency of the delta-5 desaturase enzyme. A reduction in the catalytic activity or protein abundance of FADS1, often due to a specific genetic polymorphism, leads to an altered availability of its substrates and products. [7] Specifically, this results in an increase in eicosatrienoyl-CoA (C20:3) and a decrease in arachidonyl-CoA (C20:4), which subsequently translates into altered concentrations of glycerophospholipids. [7] For instance, increased PC aa C36:3 concentrations and reduced PC aa C36:4 concentrations are observed, with the ratio between these product-substrate pairs, such as [PC aa C36:4]/[PC aa C36:3], serving as a robust indicator of FADS1 reaction efficiency. [7] A single nucleotide polymorphism (rs174548) in FADS1 has been shown to explain a substantial portion, 28.6%, of the total variance in the population for related metabolite concentrations. [7]
Systemic Relevance of Lipid Homeostasis
The precise regulation of fatty acid metabolism and glycerophospholipid synthesis is critical for maintaining overall physiological homeostasis across various tissues and organs. LCPUFAs and glycerophospholipids are not merely structural elements but are integral to cell signaling, inflammatory responses, and the proper functioning of the cardiovascular and nervous systems. Variations in the synthesis efficiency of these key biomolecules, driven by genetic factors such as FADS1 polymorphisms, can lead to distinct alterations in an individual's lipid profile. [7] These changes in circulating lipid species can have widespread systemic consequences, influencing a range of intermediate phenotypes and potentially impacting susceptibility to various health conditions.
There is no information about 'fenson' in the provided context.
Longitudinal Cohort Investigations and Phenotypic Spectrum
Large-scale longitudinal cohort studies have been instrumental in understanding the population-level dynamics of various traits. The Framingham Heart Study (FHS) is a prime example, initiated with an Original Cohort of 1644 spouse pairs, followed by an Offspring cohort of 5124 individuals, and a Third Generation cohort of 4095 individuals, with examinations occurring approximately every four years. [8] This multi-generational design allows for the investigation of temporal patterns and a broad range of phenotypes collected over decades, including pulmonary function measures, metabolic traits, kidney function, endocrine traits, hemostatic factors, and hematological phenotypes. [1] The extensive phenotypic data, including spirometry measurements, blood biomarkers, and anthropometric data, are publicly available and have been used in numerous genome-wide association studies (GWAS) to identify genetic loci associated with complex traits. [8]
Another significant longitudinal investigation is the Northern Finland Birth Cohort of 1966 (NFBC1966), a birth cohort from a founder population where traits were measured at the 31-year examination, including insulin, glucose, CRP, total cholesterol, HDL, and triglycerides. [9] Such birth cohorts offer unique insights by factoring out age-specific effects and studying individuals across the full distribution of disease-associated quantitative traits, potentially revealing loci with broader phenotypic effects compared to case-control designs. [9] The Health Aging and Body Composition (Health ABC) cohort has also contributed to understanding circulating inflammatory markers and cancer risk, demonstrating the diverse applications of long-term population studies. [10]
Cross-Population Comparisons and Ancestry Considerations
Population studies frequently involve cross-population comparisons to identify genetic and environmental factors contributing to trait variability. The Framingham Heart Study participants are predominantly self-identified white individuals of European descent, which provides a relatively homogenous genetic background for identifying common variants, yet limits the direct generalizability of findings to other ancestries. [8] Similarly, the Women's Genome Health Study (WGHS) focused on self-reported Caucasian participants, examining associations such as that between ABO histo-blood group antigen and soluble ICAM-1. [11] These studies highlight the importance of understanding the ancestral composition of cohorts when interpreting genetic associations.
The Northern Finland Birth Cohort of 1966 represents a founder population, offering a distinct genetic context for discovering novel loci for metabolic traits that may be more difficult to replicate in outbred populations. [9] Beyond single-cohort studies, collaborative efforts across multiple populations, such as analyses involving 16 European population cohorts for lipid levels, enable researchers to assess the consistency of genetic associations across diverse European populations and identify common variants contributing to polygenic dyslipidemia. [12] Such cross-population studies are crucial for understanding population-specific effects and the broader applicability of genetic findings.
Epidemiological Associations and Methodological Rigor
Epidemiological studies routinely investigate prevalence patterns, incidence rates, and their associations with various demographic and socioeconomic factors. Across multiple cohorts, numerous traits have been examined for their epidemiological correlates, including pulmonary function measures (FEV1, FVC, FEF25–75), kidney function markers (serum creatinine, GFR, cystatin C), and metabolic traits (lipids, CRP, glucose, insulin). [1] Studies consistently adjust for key demographic and lifestyle factors such as age, sex, body mass index (BMI), smoking status (never, former, current, pack-years), height, menopausal status, and hormone therapy use to isolate the specific effects of genetic variants or other exposures. [1]
Methodological rigor in these studies involves careful consideration of study designs, sample sizes, and statistical approaches. For instance, pulmonary function measures are often analyzed as cross-sectional percent of predicted values or as annual rates of decline, calculated by fitting slopes to longitudinal data. [1] Genotyping quality control is paramount, with markers excluded for low call rates, deviation from Hardy-Weinberg Equilibrium, or low minor allele frequency. [9] Advanced statistical methods, including identity-by-descent (IBD) analysis to manage relatedness within families, variance component analysis, and meta-analysis techniques, are employed to ensure robust and generalizable findings, even when combining data from multiple studies. [9]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| chr4:40241127 | N/A | fenson measurement |
| chr14:56956071 | N/A | fenson measurement |
| chr11:116474554 | N/A | fenson measurement |
| chr6:25410318 | N/A | fenson measurement |
| chr7:87067398 | N/A | fenson measurement blood metabolite level |
| chr10:123556616 | N/A | fenson measurement |
| chr2:62322310 | N/A | fenson measurement |
| chr4:62993388 | N/A | fenson measurement |
| chr5:58025046 | N/A | fenson measurement |
| chr1:63017624 | N/A | fenson measurement |
References
[1] Wilk, J. B., et al. "Framingham Heart Study genome-wide association: results for pulmonary function measures." BMC Medical Genetics, vol. 8, no. S1, 2007, p. S8. PubMed, PMID: 17903307.
[2] Ferrucci, L., et al. "Common variation in the beta-carotene 15,15'-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study." Am J Hum Genet, 2009.
[3] Grant, S.F., et al. "Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes." Nat Genet, 2006.
[4] Reiner, A.P., et al. "Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein." Am J Hum Genet, 2008.
[5] Vasan RS. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Med Genet, vol. 8, suppl. 1, 2007, S2.
[6] Helgadottir, A., et al. "A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction." Science, 2007.
[7] Gieger, Christian, et al. "Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum." PLoS Genetics, vol. 4, no. 11, 2008, e1000282.
[8] Dehghan A. "Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study." Lancet, vol. 372, no. 9654, 2008, pp. 1959–1965.
[9] Sabatti, Chiara, et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nature Genetics, vol. 41, no. 1, 2009, pp. 35-42.
[10] Melzer, David, et al. "A genome-wide association study identifies protein quantitative trait loci (pQTLs)." PLoS Genetics, vol. 4, no. 5, 2008, e1000072.
[11] Pare G. "Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women." PLoS Genet, vol. 4, no. 7, 2008, e1000118.
[12] Aulchenko, Yurii S., et al. "Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts." Nature Genetics, vol. 41, no. 1, 2009, pp. 47-55.